Highlights
- 1
- 2
- 3
Publications
Funding
Active
11 grants- MPIR01AR084711-01A1Personalized Immunomonitoring to Understand Juvenile DermatomyositisNational Inst of Arthritis & Musculoskeletal & Skin Diseases · 2025–2030
- Sub-PIU01AI187063-02Computational Modeling of Influenza Immunity (CMII)National Institute of Allergy and Infectious Diseases · 2025–2029 · via University of Chicago
- Sub-PI75N93021C00014NIAID Centers of Excellence for Influenza Research and Response (CEIRR)National Institute of Allergy and Infectious Diseases · 2021–2028 · via Icahn School of Medicine at Mount Sinai
- KPP50AR070594-10Center for Lupus ResearchNational Inst of Arthritis & Musculoskeletal & Skin Diseases · 2022–2027
- Sub-PIU01AI144616-07DIVINCI: Dissection of Influenza Vaccination and Infection for Childhood ImmunityNational Institute of Allergy and Infectious Diseases · 2021–2027 · via St. Jude Children's Research Hospital
- MPIU19AI168632-02Early life respiratory viral infections shape immune development trajectories- Project 1National Institute of Allergy and Infectious Diseases · 2023–2027 · via St. Jude Children's Research Hospital
- Co-IU01AI165452-05A deep longitudinal analysis of next generation influenza vaccines in older adults.National Institute of Allergy and Infectious Diseases · 2022–2026 · via The Jackson Laboratory for Genomic Medicine
- Sub-PI75N93019C00051Collaborative Influenza Vaccine Innovation Centers (CIVICs) Component A: Vaccine CenterNational Institute of Allergy and Infectious Diseases · 2025–2026 · via Icahn School of Medicine at Mount Sinai
- Sub-PI75N93019C00051Common cold coronavirus imprinted immunity in severe COVID to characterize broad coronavirus protective responses (Option 23)National Cancer Institute · 2024–2026 · via Icahn School of Medicine at Mount Sinai
- Sub-PI75N93019C00051CRUIVV - Center for Research on Universal Influenza Virus Vaccines (Option 6)National Institute of Allergy and Infectious Diseases · 2025–2026 · via Icahn School of Medicine at Mount Sinai
- Sub-PIU01AI153700-05The "Dynamics of the immune responses to repeat influenza vaccination exposures" (DRIVE) StudyNational Institute of Allergy and Infectious Diseases · 2021–2026 · via University of Chicago
Completed grants (18)
- Sub-PI75N93019C00051CRUIVV - Center for Research on Universal Influenza Virus Vaccines (Option 5)National Cancer Institute · 2024–2025 · via Icahn School of Medicine at Mount Sinai
- Sub-PIP01AI165077-01S1PanCorVac (Center for Pan-Coronavirus Vaccine Development)National Institute of Allergy and Infectious Diseases · 2021–2025 · via University of Wisconsin· 2 renewals
- PIU19AI082724-15Principal Project: B cell response underlying Celiac disease antibody and autoantibody responsesNIAID · 2009–2025 · via NIH RePORTER
- Sub-PI75N93019C00051CRUIVV - Center for Research on Universal Influenza Virus Vaccines (Option 4)National Cancer Institute · 2023–2024 · via Icahn School of Medicine at Mount Sinai
- Sub-PI75N93019C00051CRUIVV - Center for Research on Universal Influenza Virus Vaccines (Option 3)National Cancer Institute · 2022–2023 · via Mount Sinai School of Medicine
- Sub-PIP01AI097092-09Toward a Universal Influenza Virus VaccineNational Institute of Allergy and Infectious Diseases · 2021–2023 · via Icahn School of Medicine at Mount Sinai
- Sub-PI75N93019C00051 Option 17ACRUIVV - Center for Research on Universal Influenza Virus Vaccines (Option 17A)National Cancer Institute · 2021–2023 · via Mount Sinai School of Medicine
- PIOPP1214158Turning influenza into measles via MOsaic NaturalBill & Melinda Gates Foundation · 2021–2023
- Sub-PI75N93019C00051 - Option 17CCRUIVV - Center for Research on Universal Influenza Virus Vaccines (Option 17C)National Cancer Institute · 2021–2023 · via Mount Sinai School of Medicine
- Sub-PI75N93019C00062SARS-CoV-2 B-Cell epitope mapping supplementNational Institute of Allergy and Infectious Diseases · 2021–2023 · via The Washington University (dba Washington University School of Medicine)
- Sub-PI75N93019C00051CRUIVV - Center for Research on Universal Influenza Virus Vaccines (Option 2)National Cancer Institute · 2021–2022 · via Mount Sinai School of Medicine
- Sub-PI75N93019C00051CRUIVV - Center for Research on Universal Influenza Virus Vaccines (Option 2)National Cancer Institute · 2021–2022 · via Mount Sinai School of Medicine
- Sub-PI75N93019C00051CRUIVV - Center for Research on Universal Influenza Virus Vaccines (Option 1)National Cancer Institute · 2021–2021 · via Mount Sinai School of Medicine
- PIU19AI062629-09Early Plasma Cells as a Source of Anthrax-Neutralizing AntibodiesNIAID · 2009–2014 · via NIH RePORTER
- PIR01AI076585-04The origin and consequences of receptor editing and allelic-inclusion.NIAID · 2008–2012 · via NIH RePORTER
- PIP20RR018758-06A2COBRE: OK MED RES FOUND: P2: REGULATION OF ANTIBODY PRODUCTION TO A AUTOANTIGENNCRR · 2004–2011 · via NIH RePORTER
- PIP20RR015577-06COBRE: OMRF: B CELL TOLERANCE--SECONDARY IMMUNE RESPONSENCRR · 2004–2006 · via NIH RePORTER
Clinical research
Active
1 study- PIBiorepository of healthy subjects after vaccination or infection with common vaccines and community infectious diseases or from healthy unvaccinated control subjectsWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (1)
- PIAnalysis of deidentified samples from NDV-HXP-S Clinical Protocol Phase 1 TrialIcahn School of Medicine at Mount Sinai · IRB STUDY CLOSURE (as of 2025)
News mentions
- Stress-Linked Gut Viruses May Help Tumors Evade the Immune SystemJune 25, 2026
Chronic psychological stress can help tumors evade immune attack through a chain of molecular events involving gut bacteria and viruses within those bacteria, according to a study led by Weill Cornell Medicine investigators.
- How One Flu Virus Can Hamper the Immune Response to AnotherMarch 11, 2026
Prior exposure to one strain of influenza virus may weaken children’s ability to mount an effective antibody response against their subsequent exposure to a different flu strain, according to a study led by Weill Cornell Medicine investigators.
- Common-Cold Coronavirus Could be the Key to a Better COVID-19 VaccineNovember 10, 2025
Prior exposure to coronaviruses that cause ordinary colds can boost the immune system’s ability to attack a vulnerable site on the COVID-19-causing coronavirus SARS-CoV-2, according to a study led by investigators at Weill Cornell Medicine.
- The Quest for an HIV VaccineAugust 20, 2025
Along with an international team, Dr. John Moore, has brought biomedicine closer than ever to an HIV vaccine.
- Researchers Find an Antibody that Targets Omicron and Other SARS-CoV-2 VariantsApril 7, 2023
A team led by researchers at Weill Cornell Medicine, the University of Wisconsin-Madison; Scripps Research and the University of Chicago has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including omicron, the most recent.
Show 2 more mentions
- NIH Grant Funds Lupus Research in ChildrenOctober 21, 2022
A multi-institutional team of scientists, led by researchers at Weill Cornell Medicine’s Gale and Ira Drukier Institute for Children's Health, have received a five-year $8.297 grant to continue funding a Center for Lupus Research.
- A New “Epitope” for Universal Influenza VaccinesDecember 23, 2021
The scientists, whose results are published Dec. 23 in Nature, found that a small subset of antibodies elicited by experimental and existing influenza vaccines target a site at the base, or anchor, of the influenza virus hemagglutinin (HA) protein—an “epitope” whose significance was not recognized in prior influenza antibody studies.
Mentoring
- JJJoshua Jakob Charles McgrathPostdoc mentee · since 2022